Amman, Oct. 2 (Petra)-- Amman Design Week 2026 opened its main exhibition on Friday at the Ras Al Ain Hangar, bringing together more than 90 local, regional and international designers, makers and ...

Vauxhall has unveiled a radical new look for its famous ‘Griffin’ logo. Now into its 13th generation, the Griffin logo can trace its roots back through 700 years according to Vauxhall, with its first ...

Copilot now handles completions, nearby edits and longer-distance edits with one unified model. The revamped experience supports progressive ghost text and Tab-Tab-Tab pattern propagation. The earlier ...

Revolution Medicines recently made history with the approval of its RAS inhibitor Rasonque for advanced pancreatic cancer. But behind RevMed is an entire field of biotechs working to broaden the reach ...

The U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one ...

The FDA approved daraxonrasib, the first targeted therapy for metastatic pancreatic adenocarcinoma, citing a survival benefit vs chemotherapy. The FDA approved daraxonrasib (Rasonque; Revolution ...

The FDA has approved the first RAS-targeted therapy for metastatic pancreatic cancer, offering a new treatment option for patients with previously treated disease. Daraxonrasib (Rasonque, Revolution ...

Unmanned Surface Vessel Division 12 (Sea Hunter) and 13 (Sea Hunter) conduct unit level training underway in San Diego Bay, California, May 1, 2025. US Navy photo The Navy’s portfolio acquisition ...

b RAS G12, G13 or Q61 mut or no RAS mut identified. This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting II. This abstract does not include a full text component.

At the moment, RevMed remains keenly focused on its mission to bring daraxonrasib to the masses and continue developing new medicines that target RAS. (Darren Incorvaia) This year’s meeting of the ...

Current therapies offer limited benefit for patients with previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC). Aberrant activation of the RAS pathway is the key driver of PDAC, with ...